Bristol Myers Squibb has axed the degrader-antibody conjugate (DAC) it bought from Orum Therapeutics for $100 million, ...
The company has voluntarily stopped enrolling new patients in the studies in response to reports of mostly mild or moderate ...
Artelo Biosciences’ oral dual cannabinoid agonist showed weight loss comparable to the GLP-1 receptor agonist semaglutide in obese mice. | Artelo Biosciences’ oral dual cannabinoid agonist showed ...
North Immunology has decided its path to taking its atopic dermatitis (AD) drug into the clinic involves going public via a ...
New-look Novo is digging deeper into its metabolic roots with three new obesity programs purchased from New York biotech Kallyope. | New-look Novo is digging deeper into its metabolic roots with three ...
A new biotech has sprung out of stealth with a bold vision to develop the “greatest therapeutic of all time”—a drug that can ...
Novo’s race to rejuvenate its cardiometabolic portfolio has seen the rebranded Danish pharma pen a $1.4 biobucks pact with ...
A phase 2b study of Longeveron’s stem cell therapy in a pediatric heart disease has missed its primary endpoint, prompting ...
Electra Therapeutics is the latest biotech to overshoot its own IPO expectations this year, with the inflammation-focused company bringing in $350 million from this morning’s Nasdaq listing. | Electra ...
Novartis has extended its losing streak, stopping an amyotrophic lateral sclerosis (ALS) program after flunking a phase 2 ...
The FDA cleared Medtronic’s LigSure RAS Maryland jaw vessel sealer-divider to be used in combination with the device maker’s Hugo robotic-assisted surgery system. The device is geared toward providing ...
Lisata began hunting for an exit after a planned merger with Kuva Labs fell apart last month, which led the company to lay off 72% of its workforce, including its chief medical officer. Kuva had ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results